irsogladine has been researched along with Gastroduodenal Ulcer in 3 studies
irsogladine: RN given refers to parent cpd; MN 1695 refers to maleate salt
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here, we compare the efficacy of the gastromucoprotective drug irsogladine with omeprazole in preventing NSAID-induced esophagitis, peptic ulcers, and small-intestinal mucosal injury in healthy subjects." | 9.17 | Preventive effect of irsogladine or omeprazole on non-steroidal anti-inflammatory drug-induced esophagitis, peptic ulcers, and small intestinal lesions in humans, a prospective randomized controlled study. ( Abe, Y; Higuchi, K; Inoue, T; Ishida, K; Kawakami, K; Kojima, Y; Kuramoto, T; Murano, M; Narabayashi, K; Nouda, S; Takeuchi, T; Tokioka, S; Umegaki, E; Yoda, Y, 2013) |
| " Here, we compare the efficacy of the gastromucoprotective drug irsogladine with omeprazole in preventing NSAID-induced esophagitis, peptic ulcers, and small-intestinal mucosal injury in healthy subjects." | 5.17 | Preventive effect of irsogladine or omeprazole on non-steroidal anti-inflammatory drug-induced esophagitis, peptic ulcers, and small intestinal lesions in humans, a prospective randomized controlled study. ( Abe, Y; Higuchi, K; Inoue, T; Ishida, K; Kawakami, K; Kojima, Y; Kuramoto, T; Murano, M; Narabayashi, K; Nouda, S; Takeuchi, T; Tokioka, S; Umegaki, E; Yoda, Y, 2013) |
| "Irsogladine, a mucosal protective drug, was developed in Japan for the treatment of peptic ulcer disease and acute gastritis." | 4.89 | Irsogladine: overview of the mechanisms of mucosal protective and healing- promoting actions in the gastrointestinal tract. ( Akagi, M; Amagase, K; Murakami, T; Takeuchi, K, 2013) |
| "Irsogladine maleate was effective for reducing NSAID-induced small-intestinal mucosal injury." | 2.79 | Irsogladine improves small-intestinal injuries in regular users of nonsteroidal anti-inflammatory drugs. ( Hirata, Y; Isomura, Y; Kobayashi, Y; Koike, K; Suzuki, H; Watabe, H; Watanabe, Y; Yamada, A; Yamaji, Y; Yoshida, H; Yoshida, S, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kuramoto, T | 1 |
| Umegaki, E | 1 |
| Nouda, S | 1 |
| Narabayashi, K | 1 |
| Kojima, Y | 1 |
| Yoda, Y | 1 |
| Ishida, K | 1 |
| Kawakami, K | 1 |
| Abe, Y | 1 |
| Takeuchi, T | 1 |
| Inoue, T | 1 |
| Murano, M | 1 |
| Tokioka, S | 1 |
| Higuchi, K | 1 |
| Isomura, Y | 1 |
| Yamaji, Y | 1 |
| Yamada, A | 1 |
| Watanabe, Y | 1 |
| Suzuki, H | 1 |
| Kobayashi, Y | 1 |
| Yoshida, S | 1 |
| Watabe, H | 1 |
| Hirata, Y | 1 |
| Yoshida, H | 1 |
| Koike, K | 1 |
| Akagi, M | 1 |
| Amagase, K | 1 |
| Murakami, T | 1 |
| Takeuchi, K | 1 |
1 review available for irsogladine and Gastroduodenal Ulcer
| Article | Year |
|---|---|
Irsogladine: overview of the mechanisms of mucosal protective and healing- promoting actions in the gastrointestinal tract.
Topics: Animals; Anti-Ulcer Agents; Gastric Mucosa; Gastritis; Gastrointestinal Diseases; Helicobacter Infec | 2013 |
2 trials available for irsogladine and Gastroduodenal Ulcer
| Article | Year |
|---|---|
Preventive effect of irsogladine or omeprazole on non-steroidal anti-inflammatory drug-induced esophagitis, peptic ulcers, and small intestinal lesions in humans, a prospective randomized controlled study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Diclofenac; Endoscopy, Gastrointe | 2013 |
Irsogladine improves small-intestinal injuries in regular users of nonsteroidal anti-inflammatory drugs.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Capsule | 2014 |